PubMed Health⌕ Search

Biomedical subjects

B V Praveen

Publications and source records attributed to B V Praveen.

5 recordsLinked to original sources
PubMed1999

Expectant management of haemoperitoneum.

Nonoperative management was successful in 81 of the 90 patients including two patients with penetrating injury. Nine patients were operated on after an initial period of observation, eight because of continued bleeding and one because of features of peritonitis. There were four deaths. These were due to multisystem injuries and not directly related to haemoperitoneum alone. Nonoperative management is a relatively safe and effective method in management of selected cases of haemoperitoneum.

Abdominal Injuries↗
PubMed1992

A comparative study of intravesical instillation of 15(s) 15 Me alpha and alum in the management of persistent hematuria of vesical origin.

A prospective randomized, controlled study was done to compare the efficacy and safety of 15(s) 15 Me PGF2 alpha intravesical instillation and 1% alum vesical irrigation in the control of vesical hematuria which persisted even after continuous bladder irrigation with normal saline for 24 hours. Ten patients were treated with 15(s) 15 Me PGF2 alpha intravesical instillation in a dose of 1 mg daily for a maximum of 5 days. Six patients had complete cessation of macroscopic hematuria and partial control was seen in another 2 patients. Failure of control was seen in 2 patients. Nine patients were treated with 1% alum irrigation of bladder at a rate of 5 ml/min for a maximum period of 72 hours. Complete cessation of hematuria occurred in 6 patients and partial control in the other 3 patients. Bladder spasms was a common side effect of both drugs (19/19). Frequent catheter blockade (7/9) and recurrence of bleeding (3/9) were also seen with alum therapy. No systemic side effects occurred during therapy with both drugs. Alum, due to its safety and efficacy remains the drug of first choice for persistent vesical hematuria. High cost, low availability and stringent storage conditions are drawbacks for routine use of 15(s) 15 Me PGF2 alpha, however, PGF2 alpha promises to be a safe and effective alternative method and might be of great value in cases of alum failure as observed in two of our cases (9 and 10).

Administration, Intravesical↗
PubMed1989

Control of persistent vesical bleeding due to radiation cystitis by intravesical application of 15 (S) 15-methyl prostaglandin F2-alpha.

A 45 year old female who received radiotherapy for stage II-B uterine cervical cancer four and half years ago, presented with persistent hematuria due to radiation cystitis. 15 (S)-15-methyl prostaglandin F2-alpha (1 mg in 100 ml of normal saline) was instilled into the bladder daily for two days. The severity of bleeding decreased considerably. However, significant hematuria recurred 19 days later which continued despite bladder irrigation with normal saline. 1 mg of 15 (S) 15-Me PGF2 alpha mixed with hydroxyethyl cellulose gel to a volume of 10 ml was then instilled into the urinary bladder daily for three days and macroscopic hematuria ceased. Urinary frequency and urgency were the side effects which lasted for ten days. There has been no recurrence of macroscopic hematuria during the five months follow-up. In conclusion, 15 (S) 15-Me PGF2-alpha may be administered intravesically to control moderate hematuria due to radiation cystitis.

Administration, Intravesical↗